Cell Reports · 2020 · 37 citations · 65 references
MedicineEndocrinologyPharmacologyCell SignalingNeuroendocrinologySignal TransductionDiabetes ManagementDiabetes MellitusG Protein-coupled Receptor SignalingGlucagon-like Peptide-1 Receptor AgonistsGlycemic ControlIncretin-based TherapiesGlp-1 Receptor PharmacologyGlucagon-like Peptide 1 Receptor AgonismGlucagon-like Peptide 1 SignalingGlucagon-like Peptide-1 Receptor SignalingPeptide-based Glp-1 Receptor AgonistsSmall-molecule Glp-1 Receptor Agonists
Glucagon-like peptide-1 receptor (GLP-1R) agonists used to treat type 2 diabetes mellitus often produce nausea, vomiting, and in some patients, undesired anorexia. Notably, these behavioral effects are caused by direct central GLP-1R activation. Herein, we describe the creation of a GLP-1R agonist conjugate with modified brain penetrance that enhances GLP-1R-mediated glycemic control without inducing vomiting. Covalent attachment of the GLP-1R agonist exendin-4 (Ex4) to dicyanocobinamide (Cbi), a corrin ring containing precursor of vitamin B12, produces a "corrinated" Ex4 construct (Cbi-Ex4). Data collected in the musk shrew (Suncus murinus), an emetic mammal, reveal beneficial effects of Cbi-Ex4 relative to Ex4, as evidenced by improvements in glycemic responses in glucose tolerance tests and a profound reduction of emetic events. Our findings highlight the potential for clinical use of Cbi-Ex4 for millions of patients seeking improved glycemic control without common side effects (e.g., emesis) characteristic of current GLP-1 therapeutics.
65